Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors
Stuermer SH, Lechner A, Berking C (2021)
Publication Type: Journal article
Publication year: 2021
Journal
Book Volume: 44
Pages Range: 193-197
Journal Issue: 5
DOI: 10.1097/CJI.0000000000000367
Abstract
Immune-related adverse events have been described in 86%-96% of high-risk melanoma patients treated with immune checkpoint inhibitors (ICI), while in 17%-59% of cases these are classified as severe or even life-threatening. The most common immune-related adverse events include diarrhea, fatigue, hypothyroidism, and hepatitis. Bilateral uveitis and unspecific vertigo have been described in 1% of cases, respectively, in the pivotal studies of ICIs, but the affection of the vestibule-cochlear system has not been reported before. In this case series, we present 3-stage IV melanoma patients with sudden onset of otovestibular dysfunction (hearing loss and vestibulopathy), partly combined with uveitis because of ICIs. We describe detailed diagnostic work-up and therapeutic interventions and discuss possible pathogenic mechanisms of this rare and disabling event.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Stuermer, S.H., Lechner, A., & Berking, C. (2021). Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors. Journal of Immunotherapy, 44(5), 193-197. https://doi.org/10.1097/CJI.0000000000000367
MLA:
Stuermer, Suzan H., Axel Lechner, and Carola Berking. "Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors." Journal of Immunotherapy 44.5 (2021): 193-197.
BibTeX: Download